Every 10-Q that Neuraxis, Inc. (NRXS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NRXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRXS filings page.
NeurAxis, Inc. reported rapid top-line growth but continued losses for the quarter and six months ended June 30, 2026. Net sales rose to $1.93 million for the quarter and $3.54 million year-to-date, driven by broader insurance coverage following IB-Stim’s Category I CPT code and higher average selling prices. Gross margin remained high at 85.9–86.1%, yielding gross profit of $3.05 million for the six months.
Operating loss was $3.87 million and net loss $3.85 million year-to-date, slightly better than 2025 but still significant. Cash and cash equivalents increased to $8.32 million, largely from equity offerings and warrant exercises, supporting working capital of $6.32 million. Stockholders’ equity improved to $6.74 million as of June 30, 2026.
The company emphasizes going-concern risks, citing a history of operating losses and dependence on continued sales growth and external financing. It highlights a focused neuromodulation portfolio (IB-Stim and RED), expanding clinical studies, and ongoing efforts to secure broader payor coverage as key drivers of future performance.
NeurAxis, Inc. reported strong top-line growth but continued losses in its quarter ended March 31, 2026. Net sales rose to $1,607,883 from $895,655 a year earlier as adoption of its IB-Stim neuromodulation device increased following a Category I CPT code and broader insurance coverage. Gross margin improved to 86.4%, but the company still posted a net loss of $1,761,432, though smaller than the prior-year loss of $2,278,684.
Cash and cash equivalents increased to $7,078,659 and working capital to $5,328,867, helped by $2,990,361 of common stock sales under an at-the-market program and warrant exercises. Stockholders’ equity was $5,747,550. Despite these improvements, management and auditors concluded that substantial doubt exists about NeurAxis’s ability to continue as a going concern, given ongoing operating losses and reliance on future capital raises and wider insurance coverage.
The company carries Series B preferred stock with cumulative undeclared dividends of $1,215,264 and maintains warrant liabilities of $48,306. It also continues to remediate material weaknesses in internal control over financial reporting and is making installment payments on a $750,000 litigation settlement.
NeurAxis (NRXS) reported third‑quarter results with net sales of $811,414 and gross profit of $675,927. Operating loss was $2,100,085 and net loss was $2,122,796. For the nine months, revenue reached $2,601,155 with a net loss of $6,091,898.
Liquidity improved: cash was $4,377,109 at September 30, 2025, supported by $4,999,999 of common stock issued on May 22, 2025 and $1,002,991 of warrant exercises. Net cash used in operating activities was $4,498,684 for the nine months, while financing activities provided $5,204,211. Working capital showed a $1,840,599 surplus at quarter‑end.
The company recorded preferred stock dividends of $198,707 for the quarter and $619,715 year‑to‑date. Common shares outstanding were 9,886,294 as of September 30, 2025; the company reported 10,652,812 shares outstanding as of November 7, 2025.
NeurAxis terminated the NSS‑2 Bridge license with Masimo in exchange for $200,000 payable in two installments and recaptured related trademark and patent applications. Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses and dependence on broader insurance coverage adoption.
NeurAxis, Inc. reported quarterly net sales of $894,086, an increase of 46.2% versus the prior-year quarter, and six‑month net sales of $1.79 million. Cash rose by $2,291,586 to $5,988,456 at June 30, 2025, driven largely by proceeds of $4,999,999 from a May 22, 2025 common stock offering (1,538,461 shares issued) and $1,002,991 from warrant exercises.
Despite revenue growth and improved liquidity, the company reported a six‑month net loss of $3,969,102 and an accumulated deficit of $60,768,714. Management and auditors disclosed substantial doubt about the company’s ability to continue as a going concern. The company accrued a $375,000 current liability and $267,540 noncurrent liability for a tentative $750,000 litigation settlement. Series B Preferred Stock outstanding totaled 3,896,907 shares and common shares outstanding were 9,858,716 as of June 30, 2025.